Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.


The clinical advancement of HIV-1 attachment inhibitors was hindered initially by poor bioavailability. Attempts to identify improved candidates revealed that solubility and dissolution-rate-limited absorption are barriers to achieving adequate antiviral plasma levels. This was mitigated by forming nanosized drugs or by creating stabilised amorphous drug… (More)
DOI: 10.1016/j.drudis.2014.03.025